← All companies
About this company
Cancer kills 1 in 6 people, yet 95% of drugs fail because legacy artificial models lack human relevance. Calico Biosystems is the only platform testing drugs directly on native patient tumors to reliably predict clinical outcomes. By merging experimental human data with digital modeling (NAMs), we identify potent synergies and slash R&D timelines by 24 months. We provide drug developers with a Biological Truth Layer to future-proof pipelines against the FDA Modernization Act 2.0. Poised to capture 8% of a $250B market by 2030, Calico replaces high-attrition animal testing with human-centric certainty, transforming the value chain from pharmacology to the clinic. Together, we accelerate the delivery of life changing treatments to patients with unprecedented speed and precision.